88 related articles for article (PubMed ID: 19887481)
1. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
Koukourakis MI; Giatromanolaki A; Sheldon H; Buffa FM; Kouklakis G; Ragoussis I; Sivridis E; Harris AL;
Clin Cancer Res; 2009 Nov; 15(22):7069-76. PubMed ID: 19887481
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Koukourakis MI; Giatromanolaki A; Tsoutsou P; Lyratzopoulos N; Pitiakoudis M; Kouklakis G; Chloropoulou PA; Manolas K; Sivridis E
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):492-8. PubMed ID: 20584585
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
Crane CH; Ellis LM; Abbruzzese JL; Amos C; Xiong HQ; Ho L; Evans DB; Tamm EP; Ng C; Pisters PW; Charnsangavej C; Delclos ME; O'Reilly M; Lee JE; Wolff RA
J Clin Oncol; 2006 Mar; 24(7):1145-51. PubMed ID: 16505434
[TBL] [Abstract][Full Text] [Related]
4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
Horton JK; Halle J; Ferraro M; Carey L; Moore DT; Ollila D; Sartor CI
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):998-1004. PubMed ID: 19560883
[TBL] [Abstract][Full Text] [Related]
7. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
[TBL] [Abstract][Full Text] [Related]
9. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Puthillath A; Mashtare T; Wilding G; Khushalani N; Steinbrenner L; Ross ME; Romano K; Wisniewski M; Fakih MG
Crit Rev Oncol Hematol; 2009 Sep; 71(3):242-8. PubMed ID: 19081732
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Vrdoljak E; Omrčen T; Boban M; Hrabar A
Anticancer Drugs; 2011 Feb; 22(2):191-7. PubMed ID: 21057306
[TBL] [Abstract][Full Text] [Related]
15. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
16. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
[TBL] [Abstract][Full Text] [Related]
18. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
[TBL] [Abstract][Full Text] [Related]
19. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
20. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study.
Maluta S; Dall'Oglio S; Romano M; Marciai N; Pioli F; Giri MG; Benecchi PL; Comunale L; Porcaro AB
Int J Hyperthermia; 2007 Aug; 23(5):451-6. PubMed ID: 17701536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
